Bausch + Lomb Co. (NYSE:BLCO) Receives $19.83 Average Target Price from Brokerages

Bausch + Lomb Co. (NYSE:BLCO) has received a consensus rating of “Hold” from the twelve analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.00.

BLCO has been the topic of a number of recent research reports. Royal Bank of Canada lowered their price objective on Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, February 20th. Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Wells Fargo & Company cut their price objective on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, January 16th. Stifel Nicolaus decreased their target price on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Bausch + Lomb in a report on Tuesday, February 18th.

Bausch + Lomb Trading Down 0.9 %

BLCO stock opened at $15.82 on Monday. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69. The company has a market capitalization of $5.58 billion, a PE ratio of -17.38, a price-to-earnings-growth ratio of 0.85 and a beta of 0.46. The company’s 50-day simple moving average is $17.20 and its 200 day simple moving average is $18.15. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60.

Bausch + Lomb (NYSE:BLCO) last announced its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the prior year, the business posted $0.24 EPS. The business’s revenue was up 9.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Bausch + Lomb will post 0.74 earnings per share for the current year.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC bought a new stake in Bausch + Lomb in the third quarter worth about $5,797,000. Quadrature Capital Ltd bought a new position in Bausch + Lomb during the third quarter valued at $526,000. River Road Asset Management LLC increased its position in Bausch + Lomb by 4.4% in the third quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock worth $38,974,000 after buying an additional 85,987 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Bausch + Lomb in the third quarter valued at $957,000. Finally, King Street Capital Management L.P. purchased a new position in shares of Bausch + Lomb during the 3rd quarter valued at $14,122,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.